Cingulate Inc. Operating Income
Cingulate Inc. (CING) reported Operating Income of -$5.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- Cingulate Inc. operating income (loss) for the quarter ending 2026-06-30 was -$5.41M.
- Cingulate Inc. operating income (loss) for the quarter ending 2026-03-31 was -$7.92M.
- Cingulate Inc. operating income (loss) for the quarter ending 2025-12-31 was -$5.59M.
- Cingulate Inc. operating income (loss) for the quarter ending 2025-09-30 was -$6.00M.
- Cingulate Inc. operating income (loss) for fiscal 2025 was -$19.94M.
- Cingulate Inc. operating income (loss) for fiscal 2024 was -$15.64M.
- Cingulate Inc. operating income (loss) for fiscal 2023 was -$22.76M.
- Cingulate Inc. operating income (loss) for fiscal 2022 was -$17.50M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.41M 10-Q · filed 2026-08-13 | -$13.34M 10-Q · filed 2026-08-13 | -$18.92M derived: sum of 3 quarters · filed 2026-08-13 | -$24.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$7.92M 10-Q · filed 2026-05-14 | -$13.51M derived: sum of 2 quarters · filed 2026-05-14 | -$19.51M derived: sum of 3 quarters · filed 2026-05-14 | -$24.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$5.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$11.58M derived: sum of 2 quarters · filed 2026-03-18 | -$16.23M derived: sum of 3 quarters · filed 2026-08-13 | -$19.94M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$6.00M 10-Q · filed 2025-11-13 | -$10.65M derived: sum of 2 quarters · filed 2026-08-13 | -$14.35M 10-Q · filed 2025-11-13 | -$20.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$4.65M 10-Q · filed 2026-08-13 | -$8.36M 10-Q · filed 2026-08-13 | -$14.56M derived: sum of 3 quarters · filed 2026-08-13 | -$17.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$3.71M 10-Q · filed 2026-05-14 | -$9.91M derived: sum of 2 quarters · filed 2026-05-14 | -$13.20M derived: sum of 3 quarters · filed 2026-05-14 | -$16.40M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$9.49M derived: sum of 2 quarters · filed 2026-03-18 | -$12.70M derived: sum of 3 quarters · filed 2026-03-18 | -$15.64M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$3.28M 10-Q · filed 2025-11-13 | -$6.49M derived: sum of 2 quarters · filed 2025-11-13 | -$9.44M 10-Q · filed 2025-11-13 | -$16.23M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$3.21M 10-Q · filed 2025-08-19 | -$6.15M 10-Q · filed 2025-08-19 | -$12.95M derived: sum of 3 quarters · filed 2025-08-19 | -$18.70M derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | -$2.95M 10-Q · filed 2025-05-08 | -$9.75M derived: sum of 2 quarters · filed 2025-05-08 | -$15.50M derived: sum of 3 quarters · filed 2025-05-08 | -$21.86M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$12.55M derived: sum of 2 quarters · filed 2025-03-27 | -$18.91M derived: sum of 3 quarters · filed 2025-03-27 | -$22.76M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$5.75M 10-Q · filed 2024-11-07 | -$12.11M derived: sum of 2 quarters · filed 2024-11-07 | -$15.96M 10-Q · filed 2024-11-07 | -$20.44M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$6.36M 10-Q · filed 2024-08-13 | -$10.21M 10-Q · filed 2024-08-13 | -$14.69M derived: sum of 3 quarters · filed 2024-08-13 | -$18.66M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$3.85M 10-Q · filed 2024-05-08 | -$8.33M derived: sum of 2 quarters · filed 2024-05-08 | -$12.29M derived: sum of 3 quarters · filed 2024-05-08 | -$16.34M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$8.44M derived: sum of 2 quarters · filed 2024-04-01 | -$12.49M derived: sum of 3 quarters · filed 2024-04-01 | -$17.50M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$3.97M 10-Q · filed 2023-11-13 | -$8.02M derived: sum of 2 quarters · filed 2023-11-13 | -$13.03M 10-Q · filed 2023-11-13 | -$15.67M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$4.05M 10-Q · filed 2023-08-14 | -$9.06M 10-Q · filed 2023-08-14 | -$11.71M derived: sum of 3 quarters · filed 2023-08-14 | -$26.98M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$5.01M 10-Q · filed 2023-05-10 | -$7.66M derived: sum of 2 quarters · filed 2023-05-10 | -$22.94M derived: sum of 3 quarters · filed 2023-05-10 | -$24.36M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$17.93M derived: sum of 2 quarters · filed 2023-03-10 | -$19.35M derived: sum of 3 quarters · filed 2023-03-10 | -$20.68M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$15.28M 10-Q · filed 2022-11-14 | -$16.70M derived: sum of 2 quarters · filed 2022-11-14 | -$18.03M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$1.42M 10-Q · filed 2022-08-11 | -$2.75M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$1.33M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$7.08M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |